TP53 and B-cell chronic lymphocytic leukemia: The effectiveness of first-line Ibrutinib was also evaluated in a large series of 747 CLL patients with TP53 aberrations in a nationwide study, confirming that Ibrutinib is an effective first-line treatment for CLL patients with TP53 aberrations who are treated at both large academic centers and community practice hospitals [48].